Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. HCM
stocks logo

HCM

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent
Wall Street analysts forecast HCM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HCM is 19.38 USD with a low forecast of 13.75 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast HCM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HCM is 19.38 USD with a low forecast of 13.75 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
1 Sell
Hold
Current: 14.160
sliders
Low
13.75
Averages
19.38
High
25.00
Current: 14.160
sliders
Low
13.75
Averages
19.38
High
25.00
Morgan Stanley
Equal Weight -> Underweight
downgrade
$18
2025-09-22
Reason
Morgan Stanley
Price Target
$18
2025-09-22
downgrade
Equal Weight -> Underweight
Reason
Morgan Stanley downgraded Hutchmed to Underweight from Equal Weight with a price target of $13.75, down from $18. The company reduced its commercial guidance amid a restructuring and its "lackluster" near-term growth could drive a valuation de-rating, the analyst tells investors in a research note. The firm says Hutchmed's approved assets could be entering a period of declining product life cycles and patent expirations.
BofA
Buy
upgrade
$27 -> $28
2025-07-22
Reason
BofA
Price Target
$27 -> $28
2025-07-22
upgrade
Buy
Reason
BofA raised the firm's price target on Hutchmed to $28 from $27 and keeps a Buy rating on the shares. The firm updated its model to include a revenue build for tazemetostat and adjust expectations slightly for operating expenses, the analyst tells investors in an earnings preview for its small-to-mid cap biotech coverage.
HSBC
Buy
to
Hold
downgrade
$14.70
2025-05-13
Reason
HSBC
Price Target
$14.70
2025-05-13
downgrade
Buy
to
Hold
Reason
HSBC downgraded Hutchmed to Hold from Buy with a $14.70 price target.
See All Ratings

Valuation Metrics

The current forward P/E ratio for HUTCHMED (China) Ltd (HCM.O) is 14.81, compared to its 5-year average forward P/E of 19.45. For a more detailed relative valuation and DCF analysis to assess HUTCHMED (China) Ltd 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
19.45
Current PE
14.81
Overvalued PE
344.75
Undervalued PE
-305.85

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-68.74
Current EV/EBITDA
-337.40
Overvalued EV/EBITDA
60.90
Undervalued EV/EBITDA
-198.39

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
5.55
Current PS
3.76
Overvalued PS
9.49
Undervalued PS
1.62
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

HCM News & Events

Events Timeline

(ET)
2025-11-04
19:16:43
Hutchmed finishes enrolling participants in the Phase 3 SAFFRON trial for Orpathys combined with Tagrisso.
select
2025-11-02 (ET)
2025-11-02
20:37:55
Hutchmed showcases pipeline and business advancements during R&D Updates event
select
2025-09-12 (ET)
2025-09-12
10:02:07
Hutchmed Shares Increase by 10.4%
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
02:22 AMGlobenewswire
PinnedOver 150 Acute Myeloid Leukemia Drugs in Development by 100+ Pharma Companies
  • Market Dynamics: Over 100 pharmaceutical companies are actively engaged in developing more than 150 acute myeloid leukemia (AML) drugs, indicating strong growth potential in this therapeutic area.
  • Clinical Stages: Approximately 10 AML drugs are in late-stage development while over 50 are in mid and early stages, providing a diverse pipeline to meet the increasing demand from an aging patient population.
  • Key Drugs: Various drugs, including HUTCHMED's HMPL-306 and Moleculin Biotech's Annamycin, are undergoing clinical trials at different phases, which are expected to significantly enhance treatment outcomes for AML.
  • Regulatory Support: The FDA and EMA have granted orphan drug designations to several AML therapies, indicating regulatory backing that may expedite market access for these drugs and expand treatment options for patients.
[object Object]
Preview
3.5
11-27Newsfilter
HUTCHMED to Present New Drug Data at ESMO Asia Congress 2025
  • New Drug Research Progress: HUTCHMED will present first-in-human study results of the anti-CD47 monoclonal antibody HMPL-A83 at the 2025 ESMO Asia Congress, potentially offering new treatment options for patients with advanced solid tumors and enhancing the company's competitive position in oncology.
  • Clinical Trial Results: Phase II results from the FRUSICA-2 registration study will showcase the efficacy of the fruquintinib and sintilimab combination for locally advanced or metastatic renal cell carcinoma, which could provide a more effective second-line treatment option and strengthen the company's influence in the renal cancer market.
  • Multiple Study Presentations: HUTCHMED will also present long-term efficacy analysis of sovleplenib for chronic primary immune thrombocytopenia at the ASH Annual Meeting, further solidifying its research capabilities in hematological diseases and attracting potential investor interest.
  • International Conference Participation: By showcasing research findings at international conferences in Singapore and the USA, HUTCHMED not only enhances brand visibility but also potentially fosters collaborations with global pharmaceutical companies, driving its global business expansion.
[object Object]
Preview
1.0
11-27Globenewswire
HUTCHMED to Present New Drug Data at ESMO Asia Congress 2025
  • New Drug Research Progress: HUTCHMED will present the first clinical study results of the anti-CD47 monoclonal antibody HMPL-A83 at the 2025 ESMO Asia Congress, which is expected to provide new treatment options for patients with advanced solid tumors, further solidifying the company's position in oncology.
  • Combination Therapy Results: At the same congress, HUTCHMED will report phase II results from the FRUSICA-2 registration study of fruquintinib combined with sintilimab for locally advanced or metastatic renal cell carcinoma, demonstrating potential efficacy that could enhance the company's competitiveness in the renal cancer market.
  • Multiple Study Presentations: HUTCHMED will also showcase phase II study results of surufatinib combined with chemotherapy for metastatic pancreatic cancer at the ASH Annual Meeting, which is expected to provide new data support for treatment options in this area, enhancing the company's influence in hematologic oncology.
  • Global Conference Participation: By presenting research findings at two major international conferences in Singapore and the USA, HUTCHMED not only elevates its brand visibility but also potentially attracts more investor interest in its innovative drugs' clinical potential, further driving the company's future market expansion.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is HUTCHMED (China) Ltd (HCM) stock price today?

The current price of HCM is 14.16 USD — it has decreased -0.7 % in the last trading day.

arrow icon

What is HUTCHMED (China) Ltd (HCM)'s business?

HUTCHMED (China) Ltd is an investment holding company principally engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.

arrow icon

What is the price predicton of HCM Stock?

Wall Street analysts forecast HCM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HCM is 19.38 USD with a low forecast of 13.75 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is HUTCHMED (China) Ltd (HCM)'s revenue for the last quarter?

HUTCHMED (China) Ltd revenue for the last quarter amounts to NaN USD, decreased % YoY.

arrow icon

What is HUTCHMED (China) Ltd (HCM)'s earnings per share (EPS) for the last quarter?

HUTCHMED (China) Ltd. EPS for the last quarter amounts to USD, decreased % YoY.

arrow icon

What changes have occurred in the market's expectations for HUTCHMED (China) Ltd (HCM)'s fundamentals?

The market is revising No Change the revenue expectations for HCM for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -11.33%.
arrow icon

How many employees does HUTCHMED (China) Ltd (HCM). have?

HUTCHMED (China) Ltd (HCM) has 1811 emplpoyees as of December 05 2025.

arrow icon

What is HUTCHMED (China) Ltd (HCM) market cap?

Today HCM has the market capitalization of 2.47B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free